Who are AD109 dose1- A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quviviq, Dayvigo, Suvorexant (Belsomra), Dose-matched Placebo to Suvorexant, Suvorexant High Dose (HD), Suvorexant Low Dose (LD).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ad109-dose1-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AD109 dose1- A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AD109 dose1- A (AD109 dose1- A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: orexin receptor antagonist. Area: Neurology.

phase 2 orexin receptor antagonist orexin receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AD109 dose1- A (AD109 dose1- A) — Apnimed. AD109 is a small molecule that targets the orexin receptor to treat narcolepsy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AD109 dose1- A TARGET	AD109 dose1- A	Apnimed	phase 2	orexin receptor antagonist	orexin receptor
Quviviq	DARIDOREXANT	Idorsia	marketed	Orexin Receptor Antagonist [EPC]	Orexin receptor type 1	2022-01-01
Dayvigo	LEMBOREXANT	Eisai	marketed	Orexin Receptor Antagonist [EPC]	Orexin receptor type 2	2019-01-01
Suvorexant (Belsomra)	Suvorexant (Belsomra)	Massachusetts General Hospital	marketed	Orexin receptor antagonist	Orexin receptor 1 (OX1R) and Orexin receptor 2 (OX2R)
Dose-matched Placebo to Suvorexant	Dose-matched Placebo to Suvorexant	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors)
Suvorexant High Dose (HD)	Suvorexant High Dose (HD)	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors 1 and 2)
Suvorexant Low Dose (LD)	Suvorexant Low Dose (LD)	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors 1 and 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (orexin receptor antagonist class)

Apnimed · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AD109 dose1- A — Competitive Intelligence Brief. https://druglandscape.com/ci/ad109-dose1-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing